Figure 6F summarizes the results of these studies. We found that the inhibition of β-catenin in cancer cells leads to the dissociation and removal of β-catenin-TCF4-p300 complexes from the CEGRs/ALCDs in the GPC3 gene and from the AFP promoter, resulting in the suppression of these genes and subsequent reduction of AFP and GPC3 mRNAs and proteins. The gene discussed is GPC3; the disease is cancer.